Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Public Advisory - Health Canada warns about multiple unauthorized health products that may pose serious health risks


OTTAWA, ON, Oct. 16, 2023 /CNW/ - Health Canada is advising that the following product(s) may pose serious health risks. For more information, including product photos and what you should do, visit the online safety alert:

Health Canada maintains lists of unauthorized health products that may pose serious health risks so that the public can easily identify those they may have purchased and take appropriate action. You are encouraged to check back regularly for updates.

Product

Hazard Identified

Company

Action Taken

Unauthorized health products for sexual enhancement

Black Panther #1

 

Labelled to contain yohimbe

Dépanneur Quévillon  

210 rue Quévillon,

Varennes QC

Seized from retail location  

Super Panther 7K

 

Labelled to contain yohimbe

Dépanneur Quévillon

210 rue Quévillon,

Varennes QC

Seized from retail location

Magnum Gold 24K

 

Product with similar
packaging (previously seized)
was tested and found to
contain tadalafil

Dépanneur Quévillon

210 rue Quévillon,

Varennes QC

Seized from retail location

Rhino 69 Platinum 35000  

 

Product with similar
packaging (previously seized)
was tested and found to
contain tadalafil

Dépanneur Quévillon

210 rue Quévillon,

Varennes QC

Seized from retail location

VIP Go Rhino 69K

Labelled to contain yohimbe    

Dépanneur Quévillon

210 rue Quévillon,

Varennes QC

Seized from retail location

Stay connected with Health Canada and receive the latest advisories and product recalls.

Également disponible en français

SOURCE Health Canada (HC)


These press releases may also interest you

at 03:20
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
India-Based Dhiti Omics is Now Live on SOPHiA DDMtm
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI: Appointment of Adviser
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
If You Purchased, Paid, or Provided Reimbursement for Some or All of the Price of Branded Lipitor® or its Generic Equivalent, Atorvastatin Calcium, You Could Get Money From a Settlement
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

More news about Health...


News published on and distributed by: